Platform & Partnership ModelNanoCarrier’s DDS platform and partnership-oriented monetization provide a durable business model: its proprietary delivery IP can be licensed or used in co-development, enabling scalable, low-marginal-cost revenue streams (upfront, milestones, royalties) that transfer late-stage risk to partners and support long-term commercialization paths.

High Gross MarginsSustained gross margins near 72% reflect the IP-heavy, low-variable-cost economics of nanomedicine formulations. If revenue scales, these margins create strong contribution margins and potential operating leverage, improving long-term profitability once fixed R&D and G&A are better absorbed.

Manageable LeverageRelatively low debt and a meaningful reduction in total borrowings enhance financial flexibility, lowering interest burden and preserving borrowing capacity. This structural solvency gives the company optionality to fund trials, pursue partnerships, or bridge to value-inflection events without immediate distress.

Bears Say

Declining RevenueMulti-year top-line decline undermines scale and operating leverage. Shrinking revenue limits the firm’s ability to spread fixed R&D and G&A, reduces negotiating leverage with partners, and makes it harder to reach sustainable margins absent new, durable revenue sources or commercialized products.

Chronic Cash BurnPersistent negative operating cash flow indicates structural cash burn, forcing ongoing reliance on financings or partner funding. This reduces strategic flexibility, risks shareholder dilution, and constrains the company’s ability to self-fund clinical development through the medium term without material new collaborations or licensing receipts.

Large Losses Eroding EquityVery large operating and net losses have eroded equity and produced deeply negative ROE, signaling capital destruction. Sustained losses impair the company’s ability to self-finance development, raise the cost of capital, and increase execution risk for advancing the pipeline without partner contributions or external funding.

NanoCarrier Co., Ltd. News

NANO MRNA Advances RUNX1 mRNA Clinical Trial for Osteoarthritis

The latest announcement is out from NanoCarrier Co., Ltd. ( ($JP:4571) ). NANO MRNA Co., Ltd., through its...

5M ago

NanoCarrier Advances mRNA Therapy for Osteoarthritis

NanoCarrier Co., Ltd. ( ($JP:4571) ) has provided an update. NanoCarrier Co., Ltd., through its subsidiary NANO MRNA...

8M ago

3NQ FAQ

What was NanoCarrier Co., Ltd.’s price range in the past 12 months?

NanoCarrier Co., Ltd. lowest stock price was €0.66 and its highest was €1.15 in the past 12 months.

What is NanoCarrier Co., Ltd.’s market cap?

NanoCarrier Co., Ltd.’s market cap is €70.25M.

When is NanoCarrier Co., Ltd.’s upcoming earnings report date?

NanoCarrier Co., Ltd.’s upcoming earnings report date is May 20, 2026 which is in 86 days.

How were NanoCarrier Co., Ltd.’s earnings last quarter?

NanoCarrier Co., Ltd. released its earnings results on Feb 13, 2026. The company reported -€0.016 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.016.

Is NanoCarrier Co., Ltd. overvalued?

According to Wall Street analysts NanoCarrier Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NanoCarrier Co., Ltd. pay dividends?

NanoCarrier Co., Ltd. does not currently pay dividends.

What is NanoCarrier Co., Ltd.’s EPS estimate?

NanoCarrier Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NanoCarrier Co., Ltd. have?

NanoCarrier Co., Ltd. has 75,374,160 shares outstanding.

What happened to NanoCarrier Co., Ltd.’s price movement after its last earnings report?

NanoCarrier Co., Ltd. reported an EPS of -€0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.614%.

Which hedge fund is a major shareholder of NanoCarrier Co., Ltd.?

Currently, no hedge funds are holding shares in DE:3NQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NanoCarrier Co., Ltd.

NANO MRNA Co., Ltd. engages in the research, development, and production of pharmaceuticals using micellar nanoparticles technology. The company develops biopharmaceutical products focused on the medication of cancer and other intractable diseases. It also engages in the research, development, manufacture, and sale of anti-cancer drugs based on micellar nanoparticle technology. The company was founded by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi on June 14, 1996 and is headquartered in Tokyo, Japan.